View Post

Examining resistance to breast cancer treatments

In Clinical Trials by Barbara Jacoby

By: Molly Chiu From: bcm.edu The combination of CDK4/6 inhibitors with endocrine therapy is the standard of care for patients with estrogen receptor-positive (ER+) and HER2-negative (ER+/HER2-) metastatic breast cancer. However, a subset of patients will have tumors with intrinsic resistance to this therapy and most patients will develop resistant disease at some point during treatment. Researchers at the Lester …

View Post

Abemaciclib in HR+/HER2– Advanced Breast Cancer Well-Tolerated With Manageable Adverse Effects

In Clinical Trials by Barbara Jacoby

By: Vicki Moore, PhD From: oncologynurseadvisor.com A safety analysis of the MONARCH 2 and MONARCH 3 clinical trials suggests that abemaciclib may be generally well tolerated by patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer. Findings of the analysis were reported in the journal The Oncologist. The analysis focused on safety outcomes in …

View Post

Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Business Wire cliFrom: galvnews.com Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), early stage breast cancer (eBC) from the Phase III ExteNET trial were published in Clinical Breast Cancer. The manuscript appears in the October 5, 2020 online issue accessible at https://www.clinical-breast-cancer.com/article/S1526-8209(20)30258-5/fulltext. ExteNET was a multicenter, randomized, double-blind, …

View Post

Study: Significantly Shorter Drug Therapy Is Just as Effective for Some Breast Cancer Patients as Long-Term Options

In Clinical Trials by Barbara Jacoby

By: Jyoti Shelar From: forbes.com Scientists in India have found that women identified in the early stages of breast cancer can be treated with a short-term therapy that’s as effective as its longer-term alternative. The study’s clinical trials also show lower rates of cardiac toxic effects. One in five women suffering from breast cancer has a particularly aggressive, rapidly growing …

View Post

Phase 1 Trials: What to Expect

In In The News by Barbara Jacoby

By: Andrea S. Blevins Primeau, PhD, MBA From: cancertherapyadvisor.com A phase 1 clinical trial is typically a first-in-human study of an experimental therapy, and its historical purpose was to evaluate the safety and identify potential side effects of that investigational treatment, as well as determine an appropriate dosage for use.1 The American Society of Clinical Oncology (ASCO) states that phase 1 …

View Post

Dr. Tolaney on Sequencing Strategies in Metastatic HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Sara M. Tolaney, MD, MPH From: onclive.com Sara M. Tolaney, MD, MPH, associate director of the Susan F. Smith’s Center for Women’s Cancers, director of Clinical Trials, Breast Oncology, senior physician at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses sequencing strategies in metastatic HER2-positive breast cancer. On December 20 2019, the FDA granted …

View Post

Evidence-Based Strategies Help Guide Need for ALND in Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Jessica Herger From: onclive.com Axillary lymph node dissection (ALND) is the standard of care for patients with breast cancer who have positive sentinel lymph nodes after neoadjuvant chemotherapy, said Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C). However, several evidence-based strategies may inform which patients can be spared the invasive procedure and of the toxicities associated with the approach. …

View Post

CDK4/6 Inhibitors Significantly Improved OS in Women With Advanced Breast Cancer, Studies Show

In Clinical Trials by Barbara Jacoby

By: Laura Joszt From: ajmc.com Pairing a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor with fulvestrant significantly improved overall survival (OS) for women with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer, according to 2 abstracts presented at the European Society of Medical Oncology 2019 Congress. Women with hormone receptor (HR)-positive, human epidermal growth factor 2 …

View Post

FDA Approves Acalabrutinib for CLL

In Clinical Trials by Barbara Jacoby

By: Jason M. Broderick From: onclive.com The FDA has approved acalabrutinib (Calquence) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 The approval, which was done under the FDA’s Project Orbis initiative, was based on 2 phase III randomized trials—ELEVATE-TN and ASCEND. “Today, as part of a US, Australian, and Canadian collaboration known …